NICO
Financials
Estimates*
USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 7.3m | 7.3m | 8.1m | 8.1m | 8.4m | 11.3m |
% growth | - | - | 11 % | - | 3 % | 35 % |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.7m | Series A | |
N/A | $1.7m | Series B | |
$10.0m | Series C | ||
$6.6m | Early VC | ||
$15.0m | Late VC | ||
$8.0m | Debt | ||
N/A | $12.5m | Series B | |
* | $12.5m | - | |
Total Funding | €54.5m |
Related Content
Recent News about NICO
EditNICO Corporation specializes in developing advanced technology for the field of corridor neurosurgery. The company creates innovative instruments, such as the BrainPath and Myriad, which allow surgeons to access and resect soft tissue abnormalities through smaller openings, thereby minimizing patient trauma and improving recovery times. NICO serves neurosurgeons and healthcare institutions focused on enhancing surgical outcomes and patient care. Operating in the medical device market, NICO's business model revolves around the design, manufacture, and sale of these specialized surgical tools. Revenue is generated through direct sales to hospitals and medical centers, as well as through partnerships with organizations dedicated to improving neurosurgical techniques. The company also provides a 24-hour hotline for urgent clinical requests, ensuring continuous support for its clients.
Keywords: neurosurgery, corridor surgery, BrainPath, Myriad, minimally invasive, surgical instruments, patient outcomes, healthcare, medical devices, clinical support.